A prospective comparison of thromboembolic stockings, external sequential pneumatic compression stockings and heparin sodium/dihydroergotamine mesylate for the prevention of thromboembolic complications in urological surgery.
Deep venous thrombosis and pulmonary emboli are reported to occur in up to 66% of the patients undergoing a major urological operation. Thromboembolic stockings, external sequential pneumatic compression stockings and anticoagulant agents, such as heparin sodium plus dihydroergotamine mesylate, have been suggested to decrease the risk of deep venous thrombosis and pulmonary emboli. A total of 74 evaluable patients undergoing a major urological operation was randomized to receive either thromboembolic stockings, external sequential pneumatic compression stockings, or heparin plus dihydroergotamine as prophylaxis against deep venous thrombosis and pulmonary emboli. 111Indium-labeled platelet scans, performed preoperatively and on days 1, 3 and 6 postoperatively, were used to diagnose deep venous thrombosis and pulmonary emboli. Mean patient age was 63 years and all but 1 operation was performed for neoplastic disease. Deep venous thrombosis was detected in 5 of 25 patients (20%) with thromboembolic stockings, 3 of 24 (12.5%) with external sequential pneumatic compression stockings and 2 of 25 (8%) with heparin plus dihydroergotamine. There was no difference in blood loss or complications among the groups. Although statistical significance among the treatment groups was not reached in this study, the trend to a decrease in deep venous thrombosis and pulmonary emboli with external sequential pneumatic compression stockings and heparin plus dihydroergotamine, and an absence of an increase in morbidity in these groups supports the use of these modalities to decrease the morbidity and mortality of deep venous thrombosis and pulmonary emboli.
Hansberry
K L
KL
Radiology (Department of Surgery) Service, Brooke Army Medical Center, Fort Sam Houston, Texas.
Thompson
I M
IM
Bauman
J
J
Deppe
S
S
Rodriguez
F R
FR
D000328:Adult; D001458:Bandages; D004087:Dihydroergotamine / Q000627:therapeutic use*; D004338:Drug Combinations; D005189:False Positive Reactions; D006493:Heparin / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight; D006801:Humans; D007205:Indium Radioisotopes; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000517:prevention & control*; D011446:Prospective Studies; D011655:Pulmonary Embolism / Q000000981:diagnostic imaging / Q000209:etiology / Q000517:prevention & control; D011877:Radionuclide Imaging; D011897:Random Allocation; D012307:Risk Factors; D013923:Thromboembolism / Q000000981:diagnostic imaging / Q000209:etiology / Q000517:prevention & control*; D014570:Urologic Diseases / Q000601:surgery*
D004338:Drug Combinations; D006495:Heparin, Low-Molecular-Weight; D007205:Indium Radioisotopes; C031388:heparin-dihydergot; D004087:Dihydroergotamine; D006493:Heparin